| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Internet and Businesses Online > Domain Names > Liberalization of in-Domains? |
|
Main Subject - Liberalization of in-Domains?
Communications and IT Minister Dayanidhi Maran has -as Hindustan Times reports-some advice for Indian patriots: use in According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product -domains for Websites and e-mail IDs to popularise Indian identity in the world. With India emerging as a global "labor" ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in for IT, Indian companies should change the domain names of their Websites and e-mail IDs to in-domains, just like othe lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. r countries. "In every part of the world, the practice has been to use the short form of the respective countries at the here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe end of the domain names by companies and individuals," the minister said during his first speech as IT Minister. "Duri d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ng my trips abroad, I have always noticed that people have their e-mail IDs with the initials of their country in the end ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc . For instance, in Britain, the Websites or e-mail IDs have at the end .co.uk, in Singapore it is .co.sg, in Japan it is easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi .jp, in Hong Kong it is .hk and even in Pakistan they have .co.pk. But in India, we are still reluctant to use .co.in or nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically .in. Why this hesitation?", Dayanidhi Maran has asked in an interview. Therefore the minister has been urging upon In and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ dian captains of industry, heads of organisations and individuals to switch over to use in-domains in order to indicate ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi that their website or e-mail ID originates from India. "I have made this appeal to representatives of the IT industry h ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ere, which is considered the IT capital of India. Once the tech industry migrates to this new identity, it will set a tre dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod nd for the rest to follow in letter and spirit. They need to change the domain names of their companies or organisations cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin by registering their Websites or mail IDs only once for identifying themselves with their motherland," Maran says. "Thou tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen gh we are not making it mandatory, we are coming out with a number of schemes for Indian companies or organisations to ma t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ke this transition soon. The ministry will shortly come out with an action plan to enable a smooth migration to either .c ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust o.in or .in," the IT minister explains. The Indian IT-minister seems to be aware, that it is very bureaucratic in the m y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products oment to register in-domains. Indian companies need a lot of paperwork in order to get a domain at co.in , .in itself is . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de reserved for Indian providers, not open to all Indian companies. "Foreign companies", explains Hans-Peter Oswald, the CE elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip O of ICANN Registrar Secura (https://www.domainregistry.de/in-domain.html), ,,can only register the own name at .gen.in." tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Is Your Wholesaler Dodgy or Legitimate? How to Prepare for a Job Interview Communicating In Chaotic Environments
|